Dr Reddy’s Laboratories Ltd new patent on
Preparation of lubiprostone
Jackson, Mark; Dahanukar, Vilas Hareshwar; Joseph, Suju Chuttippari; Eda, Vishnu Vardhana Verma Reddy; Ramdas, Sandip Khobare
US 20130184476, 18-JUL-2013
| IN2011CH2389 | 13-JUL-2011 priority |
NCT01674530, Phase 3
_____________________________________________________
general info in public domain
Lubiprostone (rINN, marketed under the trade name Amitiza) is a medicationused in the management of chronic idiopathic constipation and irritable bowel syndrome. It was approved by the U.S. Food and Drug Administration (FDA) for this purpose on 31 January 2006.
Lubiprostone is used for the treatment of chronic constipation of unknown cause in adults, as well as irritable bowel syndrome associated with constipation in women.
As of 20 July 2006, Lubiprostone has not been studied in children. There is current research underway to determine the efficacy in postoperative bowel dysfunction, and opioid-induced bowel dysfunction.
Synthesis:Sobrera, L. A.; Castaner, J. (2004). Drugs of the Future 29 (4): 336.
Lubiprostone received approval from the Food and Drug Administration on 29 April 2008 to treat irritable bowel syndrome withconstipation (IBS-C).
